Celyad Oncology SA (CYAD): Business Model Canvas

Key Partnerships

Celyad Oncology SA (CYAD) understands the importance of forming strong partnerships to advance its innovative cell therapy technology and bring potential treatments to patients in need. The company has established key partnerships with various organizations in the biotech, academic, and pharmaceutical sectors to support its research and development efforts.

Some of the key partnerships of Celyad Oncology include:

• Collaborations with biotech firms: CYAD collaborates with other biotechnology companies to leverage their expertise and resources in developing and commercializing cell therapy products. These collaborations help CYAD accelerate the development of its pipeline and explore new therapeutic opportunities.
• Research partnerships with academic institutions: CYAD partners with leading academic institutions to access cutting-edge research and scientific knowledge. By collaborating with top academic researchers, CYAD can advance its cell therapy platform and gain access to novel technologies and discoveries.
• Strategic alliances with pharmaceutical companies: CYAD forms strategic alliances with pharmaceutical companies to enhance its capabilities in clinical development, regulatory affairs, and commercialization. These partnerships enable CYAD to access additional funding, resources, and expertise to bring its products to market faster.
• Clinical trial partners: CYAD works with clinical trial partners to conduct rigorous and high-quality clinical trials for its cell therapy products. These partners help CYAD design and execute clinical studies, recruit patients, and analyze data to ensure the safety and efficacy of its therapies.

Key Activities

Research and development in CAR-T therapies: Celyad Oncology SA (CYAD) is dedicated to advancing research and development in Chimeric Antigen Receptor T-cell (CAR-T) therapies. Our team of scientists and researchers work tirelessly to develop innovative CAR-T therapies aimed at treating various types of cancers.

Clinical trials and testing: We conduct rigorous clinical trials to assess the safety and efficacy of our CAR-T therapies. These trials are essential for obtaining regulatory approvals and ensuring that our therapies meet the highest standards of quality and safety.

Regulatory compliance and approvals: Ensuring regulatory compliance is a crucial aspect of our business model. We work closely with regulatory authorities to secure approvals for our CAR-T therapies and adhere to all applicable regulations and guidelines throughout the development process.

Partnership management: Collaboration is key to our success. We actively seek partnerships with other companies, research institutions, and healthcare providers to advance our CAR-T therapies and bring them to market. Managing these partnerships effectively is essential for driving innovation and expanding our reach.

• Collaborating with leading academic institutions to access cutting-edge research and expertise
• Partnering with biopharmaceutical companies to leverage their resources and capabilities
• Engaging with healthcare providers to ensure that our therapies are accessible to patients

By focusing on these key activities, Celyad Oncology SA (CYAD) aims to lead the way in developing groundbreaking CAR-T therapies that have the potential to transform the treatment of cancer.

Key Resources

Scientific and medical expertise: Celyad Oncology SA (CYAD) boasts a team of highly skilled scientists, researchers, and medical professionals who have a deep understanding of the oncology field. Their expertise allows the company to develop cutting-edge therapies and stay at the forefront of cancer treatment.

Proprietary CAR-T technology: CYAD's proprietary CAR-T technology forms the backbone of its innovative therapies. This technology enables the company to engineer immune cells to specifically target cancer cells, providing patients with personalized treatment options that have the potential to be more effective and less toxic than traditional therapies.

Research and laboratory facilities: CYAD has state-of-the-art research and laboratory facilities that are equipped with the latest technology and equipment necessary for developing and testing novel cancer treatments. These facilities are essential for the company's research and development efforts.

Data from clinical trials: CYAD has access to a wealth of data from clinical trials conducted on its therapies. This data is crucial for evaluating the safety and efficacy of its treatments, obtaining regulatory approvals, and informing future research and development efforts.

• Scientific and medical expertise
• Proprietary CAR-T technology
• Research and laboratory facilities
• Data from clinical trials

Value Propositions

Innovative CAR-T Cell Therapies for Cancer Treatment: Celyad Oncology SA (CYAD) offers cutting-edge Chimeric Antigen Receptor T-cell (CAR-T) therapies that harness the power of the immune system to target and destroy cancer cells. These therapies represent a new frontier in cancer treatment, providing patients with potentially more effective and less toxic options for fighting their disease.

Personalized Treatment Options: CYAD's CAR-T cell therapies are designed to be personalized to each patient, taking into account their unique genetic makeup and the specific characteristics of their cancer. This personalized approach allows for more targeted and effective treatment, potentially improving outcomes for patients.

Potential for Higher Efficacy in Targeting Cancer Cells: By utilizing CAR-T cell therapies, CYAD has the potential to achieve higher efficacy in targeting and eliminating cancer cells compared to traditional treatment options. These therapies are engineered to specifically recognize and attack cancer cells while sparing healthy tissue, reducing the risk of side effects and improving patient outcomes.

Commitment to Advancing Cancer Immunotherapy: CYAD is dedicated to advancing the field of cancer immunotherapy through its research and development efforts. The company continually invests in innovative technologies and collaborations to improve the efficacy and accessibility of its CAR-T cell therapies, ultimately aiming to transform the way cancer is treated.

• Innovative CAR-T Cell Therapies for Cancer Treatment
• Personalized Treatment Options
• Potential for Higher Efficacy in Targeting Cancer Cells
• Commitment to Advancing Cancer Immunotherapy

Customer Relationships

Celyad Oncology SA (CYAD) places a high priority on building and maintaining strong customer relationships across various key stakeholders in the healthcare industry. The company engages with its customers through various channels and strategies to ensure effective communication and support throughout the product development and commercialization process.

• Engagement through clinical trial participation: Celyad Oncology engages with healthcare professionals and patients through the participation in clinical trials. By involving key stakeholders in the research process, the company gains valuable insights and feedback that inform the development and refinement of its oncology treatments.
• Direct support to healthcare professionals: The company provides direct support to healthcare professionals by offering educational resources, training programs, and access to expert medical advisors. By fostering strong relationships with healthcare providers, Celyad Oncology ensures that its products are effectively integrated into clinical practice.
• Patient education and advocacy: Celyad Oncology is committed to educating patients about their treatment options and advocating for their needs within the healthcare system. The company engages with patient advocacy groups and provides resources to help patients better understand their diagnosis and treatment plan.
• Ongoing communication with stakeholders: Celyad Oncology maintains ongoing communication with key stakeholders, including patients, healthcare professionals, investors, and regulatory authorities. By keeping all parties informed and engaged throughout the product lifecycle, the company builds trust and loyalty among its customer base.

Channels

Celyad Oncology SA (CYAD) utilizes a variety of channels to reach its target audience and engage with key stakeholders in the healthcare industry. These channels include:

• Direct engagement with hospitals and clinics: CYAD works closely with hospitals and clinics to educate healthcare professionals about its innovative cell therapy solutions. Through direct meetings and collaborations, CYAD aims to build strong relationships with key decision makers in the healthcare industry.
• Presentations at medical and scientific conferences: CYAD regularly presents its research findings and advancements in cell therapy at medical and scientific conferences. These presentations provide an opportunity for CYAD to showcase its expertise and share insights with a wider audience of healthcare professionals and researchers.
• Publication in scientific journals: CYAD prioritizes the publication of its research in peer-reviewed scientific journals. By sharing its findings through reputable publications, CYAD enhances its credibility and visibility within the scientific community.
• Digital platforms and social media for information dissemination: CYAD leverages digital platforms and social media channels to disseminate information about its products, research, and company updates. Through active engagement on social media platforms, CYAD can reach a broader audience and connect with patients, caregivers, and other stakeholders in the healthcare ecosystem.

Customer Segments

The customer segments for Celyad Oncology SA (CYAD) can be broadly categorized into four key groups:

• These individuals are the end users of CYAD's innovative cell therapy products targeting various types of cancers. They rely on CYAD's treatments to improve their chances of survival and quality of life.
• CYAD's products offer a promising alternative to traditional treatments such as chemotherapy and radiation therapy, particularly for patients with advanced or hard-to-treat cancers.

• Oncologists and other healthcare professionals play a crucial role in prescribing and administering CYAD's therapies to their patients.
• They are key influencers in the treatment decision-making process and are responsible for monitoring patient outcomes and managing any potential side effects.

• Academic researchers and institutions collaborate with CYAD on preclinical and clinical studies to further advance the field of cell therapy and develop new treatment options for cancer patients.
• These partners contribute valuable scientific insights and data that drive CYAD's research and development efforts.

• Other biopharmaceutical companies, investors, and industry stakeholders are interested in CYAD's cell therapy platform and pipeline of product candidates.
• They may collaborate with CYAD on strategic partnerships, licensing agreements, or financing opportunities to support the company's growth and commercialization efforts.

Cost Structure

Celyad Oncology SA (CYAD) operates with a structured cost model to support its innovative research and development activities in the field of immuno-oncology. The cost structure of CYAD includes:

• High R&D expenditure: CYAD invests significantly in research and development activities to advance its pipeline of chimeric antigen receptor (CAR) T-cell therapies. This includes funding preclinical studies, clinical trials, and the development of new therapeutic candidates.
• Manufacturing and production costs: As a biopharmaceutical company, CYAD incurs costs related to the manufacturing and production of its CAR T-cell therapies. This includes expenses for equipment, raw materials, and personnel to produce these innovative treatments.
• Clinical trial and regulatory expenses: CYAD conducts clinical trials to evaluate the safety and efficacy of its CAR T-cell therapies. These trials involve costs associated with patient recruitment, data collection, monitoring, and regulatory compliance. Additionally, the company incurs expenses for securing regulatory approvals for its treatments.
• Partnership and collaboration costs: CYAD collaborates with academic institutions, biopharmaceutical companies, and research organizations to accelerate the development of its CAR T-cell therapies. These partnerships involve costs related to licensing agreements, research collaborations, and other collaborative activities.

The cost structure of CYAD is designed to support its mission of bringing novel immunotherapies to patients with hematologic malignancies and solid tumors. By strategically allocating resources to key areas such as R&D, manufacturing, clinical trials, and partnerships, CYAD aims to drive innovation in the field of cancer treatment and improve patient outcomes.

Revenue Streams

Revenue from commercialized therapies: Celyad Oncology generates a significant portion of its revenue from the sales of its commercialized therapies. These therapies are developed to target specific indications in the oncology space, providing value to patients and healthcare providers.

Funding from research grants: One of the revenue streams for Celyad Oncology comes from research grants. These grants are typically awarded by government agencies, nonprofit organizations, or other institutions to fund the company's research and development efforts. This funding helps support the discovery and development of new therapies.

Income from licensing deals and patents: Celyad Oncology also generates revenue through licensing deals and patents. The company may license out its technology or intellectual property to other companies in exchange for upfront payments, royalties, and milestone payments. Additionally, revenue can be generated from patents that protect the company's innovative therapies and technologies.

Partnership and collaboration revenue: Another source of revenue for Celyad Oncology is through partnerships and collaborations with other biopharmaceutical companies. These partnerships may involve joint research and development efforts, co-promotion agreements, or licensing arrangements. Revenue is generated through collaboration fees, milestone payments, royalties, and profit-sharing agreements.

• Revenue from commercialized therapies
• Funding from research grants
• Income from licensing deals and patents
• Partnership and collaboration revenue